{
    "clinical_study": {
        "@rank": "143137", 
        "brief_summary": {
            "textblock": "To identify doses of fozivudine tidoxil that are well tolerated and produce measurable\n      antiviral activity.\n\n      To identify the adverse event profile that defines the maximum tolerated dose. To\n      characterize the single- and multiple-dose pharmacokinetics of fozivudine and its\n      metabolites.\n\n      To correlate the adverse event profile and antiviral activity of fozivudine with\n      pharmacokinetic parameters."
        }, 
        "brief_title": "The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this double-blind, dose-escalating study, patients receive fozivudine tidoxil at one of 5\n      dosage levels for 4 weeks and are randomized with respect to once- or twice-daily\n      administration (cohorts 2 vs. 3 and 4 vs. 5). Within each cohort, 10 patients are randomized\n      to the study drug and 2 to the placebo. At least 9 of the 12 patients enrolled in Cohort 1\n      must complete the entire 4-week course before Cohorts 2 and 3 are enrolled. At least 18 of\n      these 24 patients must complete 2 weeks of the 4-week course before Cohorts 4 and 5 are\n      enrolled."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n        Primary and secondary prophylaxis for opportunistic infection if stable and initiated at\n        least 3 months prior to study drug administration.\n\n        Patients must have:\n\n          -  HIV-positive status.\n\n          -  One HIV RNA count > 10,000 copies/ml within 30 days prior to entry, with a second\n             count at least 3-fold above or below the first value.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Active medical problems including chronic diarrhea and active opportunistic\n             infections such as cryptococcosis, Pneumocystis carinii, histoplasmosis, etc..\n\n          -  Malignancy for which systemic therapy or radiation therapy is expected to be required\n             during the study.\n\n          -  Any other disease or condition that would place a patient at undue risk or confound\n             the results of the study.\n\n        Concurrent Medication:\n\n        Excluded:\n\n        Systemic therapy for malignancy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Zidovudine or any other nucleoside reverse transcriptase inhibitor.\n\n          -  Immunomodulators within one month prior to study drug administration.\n\n          -  Investigational drugs within 30 days prior to study drug administration.\n\n          -  Systemic cytotoxic chemotherapy within 3 months prior to study drug administration.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Extended-field radiation therapy within 3 months prior to study drug administration.\n\n          -  Blood transfusion within 2 weeks prior to study drug administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002385", 
            "org_study_id": "277A", 
            "secondary_id": [
                "MF4314", 
                "96ACR-BRM1"
            ]
        }, 
        "intervention": {
            "intervention_name": "Fozivudine tidoxil", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Dose-Response Relationship, Drug", 
            "Cohort Studies", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "official_title": "Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314).", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002385"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "collaborator": {
                "agency": "Boehringer Mannheim", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Anderson Clinical Research", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1999"
    }, 
    "geocoordinates": {}
}